Palabras clave
Reposición
Dosificación
Antioxidante
Antiinflamatorio
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Reunir evidencia e identificar enfoques científicos que justifiquen el uso de ambroxol para otros fines terapéuticos. Métodos: Esta fue una revisión integradora de la literatura basada en el Sistema de Análisis y Recuperación de Literatura Médica en Línea (MEDLINE) y Science Direct y Scientific Electronic Library Online (SCIELO) Se incluyeron estudios identificados por búsqueda manual. Resultados: Preliminarmente, se recuperaron 162 artículos, 20 de los cuales fueron incluidos. Se identificaron los mecanismos de acción del ambroxol relacionados con la interacción con las proteínas de entrada viral; con pasos de reparación enzimática con función de chaperona; modulación de canales iónicos; antioxidante; antiinflamatorio; analgésico; anestésico e inmunomodulador. La investigación ha asociado el uso de altas dosis de ambroxol como una posibilidad segura de tratamiento, prevención y/o coadyuvante en enfermedades como COVID-19, Parkinson, Gaucher, alivio del dolor y como nuevas perspectivas de uso para el Sistema Respiratorio. Consideraciones finales: El reposicionamiento de ambroxol es una posibilidad ventajosa y califica como una alternativa exitosa a los nuevos enfoques de tratamiento terapéutico, donde los diferentes mecanismos de acción explorados por ABX lo habilitan como una alternativa de uso combinado con otras terapias.
Referencias
ALKOTAJI M. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. International journal of antimicrobial agents, 2020; 56(6):106192.
ARMSTRONG MJ, OKUN MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 2020; 323(6):548-560.
BAR BI, et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis.,2013; 50(2):141-5
BARAKA AM, EL-HADIDY F. Role of ambroxol as a prophylactic agent against COVID-19. Universal Journal of Pharmaceutical Research., 2021; 6(1):61-65
BOUSCARY A. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. European Journal of Pharmacology, 2020; 884:173446.
CAI L, et al. Drug repositioning based on the heterogeneous information fusion graph convolutional network. Brief Bioinform, 2021; 22(6):bbab319.
CAZAN D, et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert opinion on drug safety, 2018; 17(12):1211-1224.
CHENOT JF, et al. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Family Practice, 2014; 13; 15:45.
DE MEY C, et al. Efficacy and Safety of Ambroxol Lozenges in the Treatment of Acute Uncomplicated Sore Throat–a Pooled Analysis. Drug Research, 2016; 66(7):384-92.
FATIMA S, et al. Repurposing Immunomodulatory Drugs to Combat Tuberculosis. Frontier Immunology, 2021; 13; 12:645485.
GAIDA W, et al. Ambroxol, a Nav1.8-preferring Na (+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology, 2005; 49(8):1220-7.
KEHINDE I A, et al. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2. Journal of Molecular Graphics and Modelling, 2022; 114:108201
KERN KU, WEISER T. Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. Der Schmerz, 2015; 29 Suppl 3(Suppl 3):S89-96.
KHOURY T, et al. A synergistic effect of Ambroxol and Beta-Glucosylceramide in alleviating immune-mediated hepatitis: A novel immunomodulatory non-immunosuppressive formulation for treatment of immune-mediated disorders. Biomed Pharmacother, 2020; 132:110890.
KIM YM, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet, 2020; 57(2):124-131.
LIPPI G, et al. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Annals of translational medicine, 2020; eight (11):693.
MCNEILL a et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014; 137(Pt 5):1481-95.
MITINI-NKHOMA SC. et al. Ion Transport Modulators Differentially Modulate Inflammatory Responses in THP-1-Derived Macrophages. Journal of immunology research., 2021; 2021: 8832586
MULLIN S, et al. Ambroxol for the Treatment of Patients with Parkinson Disease with and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol., 2020; 1; 77(4):427-434.
OLALEYE OA, et al. Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein’s receptor binding domain and recombinant human ACE2. BioRxiv, 2020; 14:2020.09.13.295691.
PFEIFER S, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. European journal of medical research,1997; 24; 2(3): 129-32
PINHEIRO DCSN, et al. Atividade imunomoduladora das plantas medicinais: perspectivas em medicina veterinária, Ciência animal, 2003; 13(1): 23-32.
PITCAIRN C, et al. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. Neurobiology of disease, 2019; 122: 72-82.
PUSHPAKOM S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov., 2019; 18(1): 41-58.
RATJEN F, et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. European journal of pediatrics.1985; 374-378
REFAI M, et al. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial. European journal of cardio-thoracic surgery, 2009; 35(3):469-73.
SILVEIRA CRA, et al. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double blind, placebo-controlled trial. BMC Neurol., 2019; 9; 19(1): 20.
TANG H, et al. The application of ambroxol hydrochloride combined with fiberoptic bronchoscopy in elderly patients with severe pneumonia: A meta-analysis and systematic review. Medicine, 2022; 28-101(4): e28535.
VAN DRIEL ML, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief?.The Annals of Family Medicine, 2006; 4(6):494-9.
WANG Yu, et al. Sputum characteristics and airway clearance methods in patients with severe COVID-19. Medicine, 2020; 13; 99(46): e23257.
WAUER RR, et al. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. European journal of pediatrics, 1992; 151(5):357-63
WU X, et al. Meta‐analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. The Journal of Clinical Pharmacology, 2014; 54(11):1199-206.
XIA DH, et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor β1 and tumor necrosis factor α. Medical Oncology, 2010; 27(3): 697-701.
ZHANG H, et al. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: A network meta‐analysis. The Clinical Respiratory Journal, 2018; 12(10): 2480-2490.
ZHANG ZQ, et al. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials. American journal of perinatology, 2013; 30(7): 529-36.
ZIMRAN A, et al. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells, Molecules, and Diseases, 2013; 50(2): 134-7.